Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: A systematic review

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Wangge, Grace ^a   Klungel, Olaf H ^a   Roes, Kit C B ^b   de Boer, Anthonius ^a   Hoes, Arno W ^a   Knol, Mirjam J ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ANALYTICAL PARAMETERS; ARTICLE; BIOEQUIVALENCE; CLINICAL PROTOCOL; CLINICAL STUDY; DRUG EFFICACY; DRUG RESEARCH; HUMAN; INFORMATION PROCESSING; INTENTION TO TREAT; JOURNAL IMPACT FACTOR; MEDLINE; METHODOLOGY; NON INFERIORITY TRIAL; PARALLEL DESIGN; PER PROTOCOL ANALYSIS; PRACTICE GUIDELINE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT; VALIDATION PROCESS; DRUG THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

DRUG THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78149435107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013550     Document Type: Article

References (25)

1. Hung HMJ, Wang S-J, O'Neill R (2005) A Regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non-inferiority Trials. Biometrical Journal 47: 28-36.
2. D'Agostino R Sr, Massaro JM, Sullivan LM (2003) Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statistics in Medicine 22: 169-186.
3. D'Agostino R Sr, Massaro JM, Sullivan LM (2009) Regulatory watch: Non-inferiority-trial discussions impact new drug applications. Nat Rev Drug Discov 8: 10-11.
4. Garattini S, Bertele V (2007) Non-inferiority trials are unethical because they disregard patients' interests. The Lancet 370: 1875-1877.
5. Jones B, Jarvis P, Lewis JA, Ebbutt AF (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ 313: 36-39.
6. Senn S (2007) Active control equivalence studies. Statistical Issues in Drug Development. 2nd ed. Glasgow: John Wiley & Sons, Ltd. pp 235-247.
7. Kay R (2007) Equivalence and non-inferiority. Statistical thinking for nonstatisticians in drug regulation. Derbyshire: John Wiley & Sons Ltd. pp 173-191.
8. ICH (2001) E10: Choice of Control Group and Related Issues in Clinical Trials In: USE ICOHOTRFROPFH, editor: ICH Expert Working Group.
9. Koch A, RÃhmel J (2004) Hypothesis Testing in the ''Gold Standard'' Design for Proving the Efficacy of an Experimental Treatment Relative to Placebo and a Reference. Taylor & Francis. pp 315-325.
10. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, et al. (2006) Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement. JAMA 295: 1152-1160.
11. ICH (1998) Stastical principles for clinical trials - E9. In: Use icohotrfropfh, editor: ICH Expert Working Group.
12. CHMP (2005) Guideline on the Choice of the Non-Inferiority Margin. In: EMEa, editor: EMEA. 11 p.
13. CDER, CBER. Draft Guidance: Guidance for Industry Non-Inferiority Clinical TrialsIn: Services HaH, ed: Food and Drug Administration; 2010:66. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM202140.pdf. Accessed 2010 March 18.
14. CDER (2003) Inside Clinical Trials: Testing Medical Products in People FDA Consumer Magazine. 1 p.
15. ICH (1997) General Considerations For Clinical Trials E8. In: use. Iohotrfropfh, editor. 13 p.
16. Snapinn SM (2000) Commentary: Noninferiority Trials. Curr Control Trials Cardiovasc Med 1: 19-21.
17. Lange S, Freitag G (2005) Special Invited Papers Section: Therapeutic Equivalence - Clinical Issues and Statistical Methodology in Noninferiority Trials. Biometrical Journal 47: 12-27.
18. Le Henanff A, Giraudeau B, Baron G, Ravaud P (2006) Quality of Reporting of Noninferiority and Equivalence Randomized Trials. JAMA 295: 1147-1151.
19. McCaffrey N, Merlin T, Hille J (2006) Lack of clinical rationale provided for non-inferiority margins. Handb Health Technol Assess. 28 p.
20. CPMP (2003) Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. In: Use TEAftEoMPEoMfH, editor. 22 p.
21. CPMP (1999) Note for guidance on clinical evaluation of new vaccines. In: Products TEAftEoM, Unit HME, editors. 18 p.
22. Brittain E, Lin D (2005) A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials. Statistics in Medicine 24: 1-10.
23. Sanchez MM, Xun C (2006) Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Statistics in Medicine 25: 1169-1181.
24. Sheng D, Kim MY (2006) The effects of non-compliance on intent-to-treat analysis of equivalence trials. Statistics in Medicine 25: 1183-1199.
25. Fleming TR (2008) Current issues in non-inferiority trials. Statistics in Medicine 27: 317-332.